ALK Secures Canadian Approval for Needle-Free Anaphylaxis Treatment neffy®
Event summary
- Health Canada approved neffy® 2 mg, a needle-free nasal adrenaline spray, for emergency anaphylaxis treatment in adults and children (≥30 kg).
- neffy® is the first approved nasal adrenaline treatment in Canada, addressing a critical need for 2.5 million Canadians with severe allergies.
- ALK expects Canada to become its largest market outside Europe, with launch planned in coming months.
- ALK holds exclusive global commercialization rights for neffy® (excluding USA, Australia, New Zealand, Japan, and China) via a 2024 license agreement with ARS Pharmaceuticals.
The big picture
ALK’s approval of neffy® in Canada marks a strategic milestone in the allergy treatment market, offering a needle-free alternative that could disrupt the dominance of adrenaline autoinjectors. The approval aligns with a broader industry shift toward patient-friendly, portable, and temperature-resistant emergency treatments. With Canada expected to become ALK’s largest market outside Europe, the success of neffy® could set the stage for further global expansion.
What we're watching
- Market Penetration
- Whether ALK can establish neffy® as the preferred anaphylaxis treatment in Canada, competing with existing adrenaline autoinjectors.
- Regulatory Momentum
- The pace at which Health Canada reviews neffy® 1 mg for children weighing 15-30 kg, expected later in 2026.
- Commercial Strategy
- How ALK leverages its co-promotion agreement with ARS Pharmaceuticals in the USA to drive global market expansion.
Related topics